CN112426436A - 子宫内膜洗液及其在治疗子***方面的应用 - Google Patents
子宫内膜洗液及其在治疗子***方面的应用 Download PDFInfo
- Publication number
- CN112426436A CN112426436A CN202011338569.0A CN202011338569A CN112426436A CN 112426436 A CN112426436 A CN 112426436A CN 202011338569 A CN202011338569 A CN 202011338569A CN 112426436 A CN112426436 A CN 112426436A
- Authority
- CN
- China
- Prior art keywords
- endometritis
- lotion
- uterus
- endometrium
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004145 Endometritis Diseases 0.000 title claims abstract description 31
- 239000006210 lotion Substances 0.000 title abstract description 19
- 210000004696 endometrium Anatomy 0.000 title abstract description 8
- 210000004291 uterus Anatomy 0.000 claims abstract description 24
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- 238000005406 washing Methods 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 239000002504 physiological saline solution Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 8
- 230000002357 endometrial effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 10
- 241000588724 Escherichia coli Species 0.000 abstract description 3
- 238000011010 flushing procedure Methods 0.000 abstract description 2
- 241000283690 Bos taurus Species 0.000 description 24
- 230000002757 inflammatory effect Effects 0.000 description 10
- 230000028327 secretion Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000012173 estrus Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000009989 contractile response Effects 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Urology & Nephrology (AREA)
Abstract
本发明公开了子宫内膜洗液及其在治疗子***方面的应用，它是冲洗健康动物的子宫得到的生理盐水洗液。将子宫内膜洗液注射到患有子***的子宫内，小鼠大肠杆菌子***模型，治愈率达70%。临床试验表明牛子***有效率为70%，治愈率60%。
Description
技术领域
本发明涉及动物医药领域，具体涉及一种子宫内膜洗液及治疗子***的应用。
背景技术
多年来子宫一直被认为是无菌的。但自20世纪80年代后中期，一些研究通过对子宫内膜样本进行细菌培养分析后发现子宫内有细菌，特别是近些年通过高通量测序方法对子宫内膜样本进行研究分析，亦表明子宫内膜有细菌存在，提示了子宫内可能有细菌的定植。不良的生殖健康结果通常与子宫内细菌的定植相关，包括绒毛膜炎、***、子***等。
子***是动物产后细菌感染引起的一种常见的产科疾病，多发于奶牛、母猪、犬等，对动物的繁殖性能危害极大。病畜患子***时，炎性产物及细菌毒素等因素作用于子宫，一方面，影响子宫内膜的正常生理功能而导致周期紊乱；另一方面，直接影响输入***的活力，阻碍受精卵及胚胎着床，从而导致屡配***，有的还可继发其他生殖***疾病造成终生***。
目前，动物子***的治疗方法包括子宫灌注抗生素、全身抗生素疗法、生物学方法、激素疗法、中药制剂法等，常用的方法是子宫灌注抗菌药物或激素疗法。但随着抗菌药物的大量应用，耐药菌株不断增多，且抗菌药物、激素等的应用不可避免的或出现药物残留，间接给人类健康带来危害。而中药制剂药方复杂、操作不便、剂量大、见效慢；因此，提供一种治疗动物子***效果好，副作用小、成本低廉的药物，成为了一个亟待解决的问题。
发明内容
本发明的目的是为解决上述问题，而提供的一种子宫内膜洗液及其在治疗子***方面的应用。
子宫内膜洗液，它是冲洗健康动物的子宫得到的洗液；
所述的洗液为生理盐水洗液；
所述的健康动物为未交配过性成熟动物。
子宫内膜洗液在制备治疗子***药物方面的应用。
本发明提供了子宫内膜洗液及其在治疗子***方面的应用，它是冲洗健康动物的子宫得到的生理盐水洗液。将子宫内膜洗液注射到患有子***的子宫内，小鼠大肠杆菌子***模型，治愈率达70%。临床试验表明牛子***有效率为70%，治愈率60%。
附图说明
图1.ELISA检测生理盐水洗液对三种不同细胞因子的影响；
图2.荧光定量检测生理盐水洗液对三种不同细胞因子的影响。
具体实施方式
实施例1 生理盐水洗液治疗子***小鼠
1.生理盐水洗液的制备
选取8-10周龄健康雌性处女小鼠（SPF级ICR小鼠）作为健康供体，在无菌条件下向小鼠子宫中注射50μL生理盐水，停留2分钟后，从子宫中抽回30μL液体，得到健康小鼠生理盐水洗液。所得到的生理盐水洗液，4℃保存。
2.临床试验
1）动物模型
取SPF级ICR小鼠20只，每只小鼠向子宫内灌注浓度达到1.0×1010 CFU/mL的大肠杆菌25μL，24h后，小鼠子***模型建立成功。
2）分组及给药
将小鼠随机分为两组，每组10只小鼠，一组作为对照组，一组作为治疗组。治疗组每天使用按上述方法制备的生理盐水洗液，使用留置针向子宫内灌注健康菌液25μL，对照组向子宫内灌注生理盐水25μL，每天一次，连续 5天为一疗程。
3）治疗效果
实验结果如图1、图2所示，生理盐水对照组治愈率为0％，生理盐水洗液治疗组治愈率达到70％，和对照组相比有显著性的差异。表明本发明生理盐水洗液具有显著的治疗小鼠子***的效果。
实施例2 生理盐水洗液治疗子***奶牛
1.实验动物
从吉林省长春市某奶牛厂选取年龄相仿、体况特征相似的20头性成熟、未交配过且处在非生理期的母牛，经如下诊断：1）看有无炎性分泌物排出，检查时看到炎性分泌物或炎性分泌物排出后留下的痕迹（牛尾、尻部、飞节污秽结有脓痂），可初步确定患有临床型子***；2）直肠检查，检查子宫所处的位置、子宫角的形状、子宫大小、质地、收缩反应，卵巢有无黄体，进一步判定炎症的轻重；3）借助开膣器进行***检查，可见子宫颈口开张、充血及有炎性分泌物流出，检查脓液的量和性状，确定炎症性质和严重程度。所选的20头牛均无以上炎症症状，子宫属健康状态。
从吉林省长春市某奶牛场，选取40头患子***奶牛，经如下诊断：1）看有无炎性分泌物排出，检查时看到炎性分泌物或炎性分泌物排出后留下的痕迹（牛尾、尻部、飞节污秽结有脓痂），可初步确定患有临床型子***；2）直肠检查，检查子宫所处的位置、子宫角的形状、子宫大小、质地、收缩反应，卵巢有无黄体，进一步判定炎症的轻重；3）借助开膣器进行***检查，可见子宫颈口开张、充血及有炎性分泌物流出，检查脓液的量和性状，确定炎症性质和严重程度。受检选取的40头奶牛，子宫角明显增厚，***肿胀，均有炎性分泌物排出，属中、重度子***。
2. 生理盐水洗液的制备
选取上述健康的母牛作为健康供体，首先用0.1%的新洁尔灭溶液消毒接触牛体的器械以及母牛***部，其次使用直肠把握输精法，利用输精器向奶牛子宫当中注入300mL无菌生理盐水，停留2分钟后，从子宫中抽回150ml液体，得到健康牛生理盐水洗液。按此方法将选取的20头奶牛所得到的生理盐水洗液，全部混合后，4℃保存备用。
3.分组及给药
分组：患病奶牛随机分为对照组、治疗组，每组20头。
给药方法：治疗组每天利用输精器向子宫内注入按上述方法制备的生理盐水洗液100 mL。对照组向子宫内灌注生理盐水1次，每天1次，连续5天为一疗程。1个疗程后考察治疗结果。
4.疗效判定
分为治愈、好转、无效。治愈：临床症状消失，恢复正常发情，发情时粘液正常；好转，临床症状消失，恢复发情，但发情时粘液还有异常；无效，临床症状及子宫机能均无明显好转。
5.治疗效果
治疗结果如表1所示，生理盐水对照组治愈率为0％，生理盐水洗液治疗组治愈率达到60 %，有效率达到70%，和对照组相比有显著性的差异。表明本发明生理盐水洗液具有显著的治疗牛子***的效果。
实际生产中可采用肉牛或待屠宰的肉牛子宫洗液，治疗奶牛或种牛子***。
Claims (4)
1.子宫内膜洗液，其特征在于：它是冲洗健康动物的子宫得到的洗液。
2.根据权利要求1所述的子宫内膜洗液，其特征在于：所述的洗液为生理盐水洗液。
3.根据权利要求1或2所述的子宫内膜洗液，其特征在于：所述的健康动物为未交配过性成熟动物。
4.权利要求1所述的子宫内膜洗液在制备治疗子***药物方面的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011338569.0A CN112426436A (zh) | 2020-11-25 | 2020-11-25 | 子宫内膜洗液及其在治疗子***方面的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011338569.0A CN112426436A (zh) | 2020-11-25 | 2020-11-25 | 子宫内膜洗液及其在治疗子***方面的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112426436A true CN112426436A (zh) | 2021-03-02 |
Family
ID=74697712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011338569.0A Pending CN112426436A (zh) | 2020-11-25 | 2020-11-25 | 子宫内膜洗液及其在治疗子***方面的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112426436A (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120052093A1 (en) * | 2009-04-23 | 2012-03-01 | Cornell University | Compositions and methods for preventing and treating uterine disease |
| US20140134144A1 (en) * | 2012-07-13 | 2014-05-15 | Burim Ametaj | Use of probiotic bacterial strains as a prophylactic tool against uterine infections in pregnant female ruminants |
| CN104997571A (zh) * | 2015-07-13 | 2015-10-28 | 付静涛 | 一种提高奶牛发情率的方法 |
| CN105287644A (zh) * | 2015-09-14 | 2016-02-03 | 吉林农业大学 | 治疗奶牛隐性子***的益生菌组合活菌制剂 |
| CN106106364A (zh) * | 2016-07-29 | 2016-11-16 | 董标 | 一种提高母猪繁殖性能的养殖方法 |
| CN110946878A (zh) * | 2019-11-27 | 2020-04-03 | 沣潮医药科技（上海）有限公司 | 子宫腔液来源外泌体在制备***不育相关疾病治疗药物及辅助治疗剂中的用途 |
| CN114717150A (zh) * | 2022-04-20 | 2022-07-08 | 河北农业大学 | 一种植物乳杆菌crs33及其应用 |
-
2020
- 2020-11-25 CN CN202011338569.0A patent/CN112426436A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120052093A1 (en) * | 2009-04-23 | 2012-03-01 | Cornell University | Compositions and methods for preventing and treating uterine disease |
| US20140134144A1 (en) * | 2012-07-13 | 2014-05-15 | Burim Ametaj | Use of probiotic bacterial strains as a prophylactic tool against uterine infections in pregnant female ruminants |
| CN104997571A (zh) * | 2015-07-13 | 2015-10-28 | 付静涛 | 一种提高奶牛发情率的方法 |
| CN105287644A (zh) * | 2015-09-14 | 2016-02-03 | 吉林农业大学 | 治疗奶牛隐性子***的益生菌组合活菌制剂 |
| CN106106364A (zh) * | 2016-07-29 | 2016-11-16 | 董标 | 一种提高母猪繁殖性能的养殖方法 |
| CN110946878A (zh) * | 2019-11-27 | 2020-04-03 | 沣潮医药科技（上海）有限公司 | 子宫腔液来源外泌体在制备***不育相关疾病治疗药物及辅助治疗剂中的用途 |
| CN114717150A (zh) * | 2022-04-20 | 2022-07-08 | 河北农业大学 | 一种植物乳杆菌crs33及其应用 |
Non-Patent Citations (4)
| Title |
|---|
| NEREA M. MOLINA,等: "New Opportunities for Endometrial Health by Modifying Uterine Microbial Composition:Present or Future?", 《BIOMOLECULES》 * |
| 孙凯鑫: "子宫菌群移植对小鼠子***的治疗作用", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
| 杨增，等: "约氏乳杆菌对ＬＰＳ诱导的奶牛子宫内膜上皮细胞炎症反应的影响", 《中国兽医学报》 * |
| 桑梦琪: "奶牛生殖道益生性乳酸菌分离鉴定及其复合制剂的研究", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Garcia‐Ispierto et al. | Reproductive performance of anoestrous high‐producing dairy cows improved by adding equine chorionic gonadotrophin to a progesterone‐based oestrous synchronizing protocol | |
| CN100493600C (zh) | 一种预防及治疗奶牛子***及胎衣不下症的药物组合物 | |
| Samardžija et al. | Intrauterine ozone treatment of puerperal disorders in domestic ruminants: a review | |
| CN103316312B (zh) | 一种补益清宫合剂及其制备工艺 | |
| CN105188721B (zh) | 钨（vi）盐用于治疗非糖尿病哺乳动物的雌性不育症的用途 | |
| Palomares et al. | Oxytocin treatment immediately after calving does not reduce the incidence of retained fetal membranes or improve reproductive performance in crossbred Zebu cows | |
| CN1255135C (zh) | 防治母畜***症的中药灌注液 | |
| CN112426436A (zh) | 子宫内膜洗液及其在治疗子***方面的应用 | |
| CN108451896B (zh) | 一种用于控制动物卵泡发育和防治生殖道炎症的装置和制备方法 | |
| Sharma et al. | Causes and therapeutic management of infertility in abandoned cows of Himachal Pradesh | |
| Cui et al. | Prophylactic strategy with herbal remedy to reduce puerperal metritis risk in dairy cows: A randomized clinical trial | |
| CN1268355C (zh) | 一种治疗牛子***的中药 | |
| CN104825478B (zh) | 一种用于治疗奶牛子***的药物组合物及其灌注液的制备方法 | |
| CN104288162B (zh) | 一种奶牛用盐酸多西环素子宫注入剂及其制备方法 | |
| Modric et al. | Hormonal and antimicrobial therapy in theriogenology practice: Currently approved drugs in the USA and possible future directions | |
| CN111000653B (zh) | 控制马属动物卵泡发育、防治生殖道炎症的装置及其方法 | |
| Rahim et al. | Use of vitamin E and selenium injections as supportive treatment of retained placenta in dairy cattle | |
| CN1981826A (zh) | 一种治疗牛子宫炎的子宫灌注液 | |
| RU2392928C2 (ru) | Способ лечения и профилактики эндометритов у коров | |
| CN1463699A (zh) | 一种治疗动物子***的组合物 | |
| Aini et al. | Case Study: Open Pyometra in a Pomeranian Dog at INI Veterinary Service Clinic | |
| Gupta et al. | Evaluation of intra-uterine lugol's iodine therapy and double PGF2α shot for treatment of subclinical endometritis in dairy cattle. | |
| Trundell | Equine Reproduction: Seasonality, Endometritis, and Twinning in the Mare | |
| Amirov et al. | Uterus Diseases In Cows-Endometritis | |
| CN104491219B (zh) | 一种预防和治疗母畜子***的中药液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210302 |
|
| RJ01 | Rejection of invention patent application after publication |